Generation of TCRγδ + T cells from human embryonic stem cells.

Xueyan Zhang, Chuxin Chen, Yingjie Fu, Haibin Wu, Ning Wang, Xinyi Shi, Yongjian Zhou, Yuyou Duan

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xueyan Zhang *Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.

Chuxin Chen *Laboratory of Stem Cells and Translational Medicine, Institute for Clinical Medicine, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.

Yingjie Fu *Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.

Haibin WuDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.

Ning WangLaboratory of Stem Cells and Translational Medicine, Institute for Clinical Medicine, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.

Xinyi ShiDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China.

Yongjian ZhouDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. yongjian_zhou@outlook.com.

Yuyou DuanDepartment of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. yuyouduan@scut.edu.cn.

Funding

Foundation of Guangzhou Key Clinical Specialties (Institute of Clinical Medicine) 2024-2026National Key Research and Development Program of China 2018YFA0108201Project of Key Medical Discipline in Guangzhou 2025-2027Research Agreement between South China University of Technology and Guangzhou First People's Hospital D9194290Research Starting Funding of South China University of Technology D6201880, K5180910, K5204120, and D6212440Research Starting Funding of the Second Affiliated Hospital of South China University of Technology KY09060026

6 · The paper itself

Abstract

As a crucial lymphocyte subset, γδT cells exhibit tumoricidal properties without the constraint of major histocompatibility complex restriction. In recent years, the in vitro expansion of human peripheral blood-derived γδT cells has emerged as a promising candidate for adoptive immune cell therapy (ACT). However, given the limitations in accessing and sourcing human peripheral blood, it remains challenging to expand γδT cells to the magnitude required for clinical cancer immunotherapy. Therefore, the objective of this study was to establish an innovative approach for the in vitro differentiation of γδT cells from human embryonic stem cells (hESCs). In present study, by simulating the in vivo developmental process of γδT cells, we established stroma cell-free differentiation approach with three stages under 3D suspension culture in conjunction with using hypoxic conditions. Under our protocol, around 39% of CD34

Indexed as

Human Embryonic Stem CellsReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesCell Culture TechniquesCell DifferentiationCells, CulturedHematopoietic Stem CellsHumansReceptors, Antigen, T-Cell, gamma-deltaDirectional differentiationHematopoietic endothelial cellsHematopoietic progenitor cellsHuman embryonic stem cellsγδT cells

Identifiers

PMID41617828

DOI10.1038/s41598-026-37941-w

PMCPMC12913928

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.